Home/ Stocks/ SCYX

SCYNEXIS, Inc.

SCYX XNAS

$0.92 -0.04 (-4.35%) ▼ 15-min delayed

Open

$0.96

High

$0.96

Low

$0.91

Volume

119.5K

Market Cap

$72.75M

About SCYNEXIS, Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 29 Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	$20.60M	$-8,609,000	$-0.17
FY 2025	$20.60M	$-8,609,000	$-0.17
Q3 2025	$334.0K	$-8,591,000	$-0.17
Q1 2025	$257.0K	$-5,391,000	$-0.11

Related Market News

No specific coverage for SCYX yet. Check out our latest market news or earnings calendar.

Get SCYX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on SCYNEXIS, Inc..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.